Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms.
Is pleased to announce that the poster it presented at the American Association of Cancer Research (AACR) 2022 Annual Meeting, entitled ‘AVA6000, a novelpre|CISION™ medicine, targeted to the tumor microenvironment via Fibroblast Activation Protein (FAP) mediated cleavage’ is now available to download from the Company’s website.
The poster, which was presented by Dr. Fiona McLaughlin, Chief Scientific Officer, and Neil Bell, Chief Development Officer, describes the pre-clinical rationale for the company’s leading oncology candidate, AVA6000. AVA6000 is a FAP (fibroblast activation protein α) activated doxorubicin therapeutic and utilises Avacta’s pre|CISION™ platform to improve the safety and therapeutic index of doxorubicin.
AVA6000 has been designed to limit cell penetration of the drug, and therefore its cell killing effect, until it is specifically activated by FAP, which is in high concentration in many solid tumours compared with healthy tissues. The resulting reduced exposure of healthy tissues to active doxorubicin has the potential to significantly increase its therapeutic index by reducing the incidence of adverse effects, including cardiotoxicity and myelosuppression.
A first-in-human Phase I clinical trial (ALS-6000-101) has been initiated in the UK in a broad spectrum of high FAP expressing tumours.
The poster can be downloaded from Avacta’s website at: www.avacta.com/about/resources.
– ENDS –
For further information from Avacta Group plc, please contact:
Avacta Group plc
Alastair Smith, Chief Executive Officer
Tony Gardiner, Chief Financial Officer
Michael Vinegrad, Group Communications Director
Tel: +44 (0) 844 414 0452
